Diagnóstico y tratamiento | 16 JUL 12

Síndrome de Sjögren primario

El síndrome de Sjögren es una enfermedad autoinmune sistémica causante de una disfunción de las glándulas secretorias, lo que produce sequedad de las superficies mucosas principales.
Autor/a: Dres. Manuel Ramos-Casals, Pilar Brito-Zerón, Antoni Sisó-Almirall, Xavier Bosch BMJ 2012;344:e3821
INDICE:  1. Artículo | 2. Referencias
Referencias

Referencias

1 Ramos-Casals M, Font J. Primary Sjögren’s syndrome. In: Imboden J, Hellmann D, Stone J, eds. Current diagnosis and treatment in rheumatology . McGraw-Hill, 2007: 237-45.
2 Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
3 Wirbelauer C. Management of the red eye for the primary care physician. Am J Med 2006;119:302-6.
4 Derk CT, Vivino FB. A primary care approach to Sjögren’s syndrome. Helping patients cope with sicca symptoms, extraglandular manifestations. Postgrad Med 2004;116:49-54,59, 65.
5 Siso A, Benavent J, Bosch X, Bové A, Ramos-Casals M. Primary Sjögren syndrome in primary health care. In: Ramos-Casals M, Stone JH, Moutsopoulos HM, eds. Sjögren syndrome: diagnosis and therapeutics . Springer, 2012:501-16.
6 Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006;45:187-91.
7 Gøransson LG, Haldorsen K, Brun JG, Harboe E, Jonsson MV, Skarstein K, et al. The point prevalence of clinically relevant primary Sjögren’s syndrome in two Norwegian counties. Scand J Rheumatol 2011;40:221-4.
8 Callaghan R, Prabu A, Allan RB, Clarke AE, Sutcliffe N, Pierre YS, et al; UK Sjögren’s Interest Group. Direct healthcare costs and predictors of costs in patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 2007;46:105-11.
9 Bowman SJ, St Pierre Y, Sutcliffe N, Isenberg DA, Goldblatt F, Price E, et al. Estimating indirect costs in primary Sjögren’s syndrome. J Rheumatol 2010;37:1010-5.
10 Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
11 Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al.
European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
12 Ramos-Casals M, Daniels TE, Fox RI, Whitcher JP, Fragoulis GE, Skopouli FN, et al. Sjögren syndrome. In: Stone JH, ed. A clinician’s pearls and myths in rheumatology . Springer, 2009:107-30.
13 Ng WF, Bowman SJ. Primary Sjogren’s syndrome: too dry and too tired. Rheumatology (Oxford) 2010;49:844-53.
14 Westhoff G, Dörner T, Zink A. Fatigue and depression predict physician visits and work disability in women with primary Sjogren’s syndrome: results from a cohort study. Rheumatology (Oxford) 2012;51:262-9.
15 Theander L, Strömbeck B, Mandl T, Theander E. Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren’s syndrome? Rheumatology (Oxford) 2010;49:1177-83.
16 Segal B. Fatigue in primary Sjögren syndrome. In: Ramos-Casals M, Stone JH, Moutsopoulos HM, eds. Sjögren syndrome: diagnosis and therapeutics . Springer, 2012:129-48.
17 Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. GEMESS Study Group. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008;87:210-9.
18 Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren’s syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-62.
19 Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93.
20 Brennan M, Sankar V, Leakan R, Kleiner D, Atkinson JC, Wilkinson WE, et al. Risk factors for positive minor salivary gland biopsy findings in Sjögren’s syndrome and dry mouth patients. Arthritis Rheum 2002;4:189-95.
21 Ramos-Casals M, Brito-Zerón P, Perez-De-Lis M, Diaz-Lagares C, Bove A, Soto MJ, et al. Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren’s syndrome. J Rheumatol 2010;37:585-90.
22 Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 2011;70:968-72.
23 Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 2010;69:1103-9.
24 Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
25 Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
26 Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56.
27 Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 2007;36:246-55.
 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022